Drugs / AlloStim8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00861965 | Jan 2010 → Mar 2011 | refractory hematologic cancer | Mirror Biologics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00861107 | Aug 2009 → Mar 2011 | metastatic malignant neoplasm | Mirror Biologics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloStim-8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00861965 ↗ |
| Known as | AlloStim | “the experimental immunotherapy drug, called AlloStim” NCT00861965 ↗ |
| Modality | Vaccine | “personalized therapeutic cancer vaccine” NCT00861107 ↗ |
| Route | Intravenous | “intravenous administration of the experimental immunotherapy drug” NCT00861965 ↗ |